Fresenius Acquires Renal Solutions, Next-Gen Home Dialysis Technology
This article was originally published in The Gray Sheet
Executive Summary
The Nov. 29 acquisition of Renal Solutions Inc. (RSI) by Fresenius Medical Care is expected to give Fresenius a better hold on the home therapy market for kidney dialysis
You may also be interested in...
Breathing Easy: ALung CEO Talks Novel Hemolung Device, FDA's Breakthrough Pathway, Landmark US/UK Clinical Trials
In a deep-dive sit-down interview with Medtech Insight, ALung Technologies CEO Pete DeComo dishes on US FDA's Breakthrough Devices Program and explains why his firm's novel artificial lung device, Hemolung, is worthy of traveling the expedited pathway to agency approval. DeComo also details two pivotal Hemolung clinical trials in the US and UK, and explains why Hemolung isn't marketing the device for commercial use despite being approved in 36 countries outside the US. He also talks about a future portable version of Hemolung, but noted that's not where ALung is focused right now. "Our first task is that first-generation technology – to get it to market, make it the standard-of-care, and then, if you are successful with all of that, you can do all of those wonderful other things as it relates to portability and wearability," DeComo says.
Life Sciences Greenhouse Plants Medtech Seeds In Pittsburgh
ALung CEO Pete DeComo says the start-up's novel Hemolung device might never have seen the light of day if it weren't for the support of the company's local community and, in particular, investment firm Pittsburgh Life Sciences Greenhouse. And ALung isn't the only Pittsburgh medtech firm the Greenhouse is aiding – there are currently 25 device and diagnostics start-ups in its portfolio.
Home Dialysis Equipment Makers Eye Market Expansion Opportunities
Dialysis equipment vendors are ramping up efforts to ensure that patients with irreversible kidney failure are aware home dialysis is an option